重视胆汁淤积性肝病的诊断和药物治疗

doi:10.3969/j.issn.1672-5069.2016.06.001

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (6): 641-643.doi: 10.3969/j.issn.1672-5069.2016.06.001

• 述评 • 下一篇

重视胆汁淤积性肝病的诊断和药物治疗

施漪雯，尤红

100050北京市首都医科大学附属北京友谊医院肝病中心/国家消化系统疾病临床医学研究中心/北京市肝硬化转化医学重点实验室

收稿日期:2016-09-10 出版日期:2016-11-10 发布日期:2016-11-28
通讯作者: 尤红，E-mail:youhong30@sina.com

Diagnosis and medical treatment of patitents with cholestatic liver diseases

Shi Yiwen，You Hong.

Centre for Liver Diseases，Friendship Hospital，Capital Medical University，Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis，National Clinical Research Center for Digestive Diseases，Beijing 100050，China

Received:2016-09-10 Online:2016-11-10 Published:2016-11-28

摘要/Abstract

关键词: 胆汁淤积性肝病, 诊断, 药物治疗

Key words: Cholestasis liver diseases, Diagnosisl, Treatment

施漪雯，尤红. 重视胆汁淤积性肝病的诊断和药物治疗[J]. 实用肝脏病杂志, 2016, 19(6): 641-643.

Shi Yiwen，You Hong.. Diagnosis and medical treatment of patitents with cholestatic liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 641-643.

[1] 中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识（2015）. 中华肝脏病杂志，2015，23:924-933.
[2] EASL Clinical Practice Guidelines:management of cholestatic liver diseases. J Hepatol，2009，51:237-267.
[3] Zhang DK，Chen M，Liu Y，et al. Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis:A preliminary study. Clin Radiol，2014，69:836-840.
[4] Lammers WJ，Hirschfield GM，Corpechot C，et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology，2015，149:1804-1812.e1804.
[5] Carbone M，Sharp SJ，Flack S，et al. The UK-PBC risk scores:Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology，2016，63:930-950.
[6] Zhang LN，Shi TY，Shi XH，et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis:results of a 14-year cohort study. Hepatology，2013，58:264-272.
[7] Mitchell SA，Bansi DS，Hunt N，et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology，2001，121:900-907.
[8] Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis:throwing the urso out with the bathwater Hepatology，2009，50:671-673.
[9] Sinakos E，Marschall HU，Kowdley KV，et al. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis:Relation to disease progression. Hepatology，2010，52:197-203.
[10] Trauner M，Halilbasic E，Kazemi-Shirazi L，et al. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. Dig Dis，2014，32:631-636.
[11] Neuschwander-Tetri BA，Loomba R，Sanyal AJ，et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic，non-alcoholic steatohepatitis（FLINT）:a multicentre，randomised，placebo-controlled trial. Lancet， 2015，385:956-965.
[12] Hirschfield GM，Mason A，Luketic V，et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology， 2015，148:751-761.e758.
[13] Nevens F，Andreone P，Mazzella G，et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med，2016，375:631-643.
[14] Cheung AC， Lapointe-Shaw L，Kowgier M，et al. Combined ursodeoxycholic acid（UDCA） and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther，2016，43:283-293.
[15] Levy C，Peter JA，Nelson DR，et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther，2011，33:235-242.
[16] Zhang Y，Li S，He L，et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis. Drug Des Devel Ther，2015，9:2757-2766.
[17] Hegade VS，Khanna A，Walker LJ，et al. Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score. Dig Dis Sci，2016，[ahead of print].
[18] Hosonuma K，Sato K，Yamazaki Y，et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol，2015，110:423-431.

重视胆汁淤积性肝病的诊断和药物治疗

Diagnosis and medical treatment of patitents with cholestatic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[3]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[4]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[5]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[6]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[7]	丁雯瑾, 范建高. 胆汁淤积性肝病相关并发症的处理^*[J]. 实用肝脏病杂志, 2019, 22(6): 938-940.
[8]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[11]	陆伦根. 胆汁淤积性肝病的正确认识与科学管理[J]. 实用肝脏病杂志, 2019, 22(5): 754-757.
[12]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[13]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[14]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.